All News

Medicaid expansion has enhanced cancer care in Louisiana, boosting access to treatments like CAR T-cell therapy and improving breast cancer screening initiatives.

With ACA subsidies and key CMS payment models ending in 2025, premiums are set to rise, shifting costs to consumers and employers.

A study identifies tumor stage and stoma status as key drivers of diminished quality of life among patients with colorectal cancer.

While artificial intelligence showed empathy and precision in respiratory health care, its equitable adoption is paramount to prevent the widening digital divide, as highlighted at the European Respiratory Society Congress 2025.

Secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves overall survival in platinum-sensitive recurrent ovarian cancer.

This approval makes durvalumab with FLOT chemotherapy the first perioperative immunotherapy for resectable gastric or gastroesophageal junction adenocarcinoma.

A case-crossover study found that extreme heat increased mortality between 10% and 18%, with higher risks in vulnerable groups.

Non-DNMT3A CHIP subtypes raised heart failure risk in a recent analysis, offering new insights for prevention and targeted management.

US adults with arthritis have higher odds of stress, urge, and mixed urinary incontinence, highlighting the need for routine screening and integrated care.

Exposure to antibiotics is linked to higher risk of biologic discontinuation in psoriasis, potentially through gut microbiota changes.

The 2024-2025 US influenza season hit older adults hardest, driving hospitalizations and costs, while vaccine coverage remained below targets.

A large cohort study found adolescents and young adults starting TMP-SMX faced a higher 30-day risk of acute respiratory failure than those on other antibiotics.

RSV vaccines protect adults 60 years and older against illness, but effectiveness declines over 2 seasons, especially in those who are immunocompromised.

Discontinuing GLP-1 use before or early in pregnancy raises gestational weight gain, birth weight percentile, and the risk of pregnancy complications.

Data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

The quick turnaround between the introduction of Medicaid work requirements and implementation could leave many states spread thin, explains William Schpero, PhD, MPhil, MPH

Phase 3 ADORING data show tapinarof improves skin, itch, and sleep in children with atopic dermatitis, with similar efficacy and safety in those with comorbidities.

Chimeric antigen receptor T-cell therapies, along with bispecific antibodies, have changed the treatment paradigm for patients with relapsed or refractory mantle cell lymphoma.

A new analysis based on two prospective trials helps clarify the roles of chemotherapy and radiotherapy.

Chronic kidney disease now affects more than 788 million adults globally, with rising prevalence, increasing mortality, and substantial contributions to cardiovascular deaths

A study identified 32 dysregulated cytokines and 5 key signaling hubs in idiopathic pulmonary fibrosis (IPF), mapping a complex network of profibrotic pathways that may serve as future therapeutic targets.

A combined assessment of genetic, serologic, and clinical factors may enhance early recognition of patients with RA who are most at risk for ILD.

Modern ibrutinib-based approaches substantially narrow the traditional survival gap observed in CLL.

Most US patients eligible for hepatitis B virus (HBV) treatment remain untreated, raising risks of liver disease and complications.

Baricitinib demonstrated significant reductions in disease activity in postmenopausal women with frontal fibrosing alopecia over 12 weeks.

The FDA expanded approvals for key medications, enhancing treatment options for atopic dermatitis, inflammatory bowel disease, type 2 diabetes, and more.

The FDA has approved pembrolizumab and enfortumab vedotin for muscle-invasive bladder cancer (MIBC), offering new hope for patients ineligible for cisplatin.

Individuals told their absolute risk of HIV had higher interest in pre-exposure prophylaxis (PrEP) compared with those told relative risk.